Roth Capital Nearly Doubles PT on Cytori (CYTX) to $6; Positive on Phase III STAR for Scleroderma
Tweet Send to a Friend
Roth Capital bumps its price target on Cytori Therapeutics (Nasdaq: CYTX) from $3.50 up to $6 and reaffirms its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
